Lexicon Pharma: Inpefa’s Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value
Lexicon matters because it shows how a single approved drug can still be a concentrated, execution-sensitive biotech position. For long-term investors, the bigger issue is whether commercial access, payer adoption, and financing needs can convert clinical promise into durable portfolio value.
